This disparity may be explained by that JAK2V617F expression in our study was more consistent with heterozygous JAK2V617F mutation in essential thrombocythemia (ET) patients because endogenous JAK2 gene was still present. The gene discussed is JAK2; the disease is essential thrombocythemia.